Semin Liver Dis 2021; 41(01): 087-102
DOI: 10.1055/s-0040-1719174
Review Article

New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease

Phillipp Hartmann
1   Department of Pediatrics, University of California San Diego, La Jolla, California
2   Department of Medicine, University of California San Diego, La Jolla, California
,
Bernd Schnabl
2   Department of Medicine, University of California San Diego, La Jolla, California
3   Department of Medicine, VA San Diego Healthcare System, San Diego, California
› Institutsangaben

Funding This work was supported by National Institutes of Health grants K12 HD85036 (to P.H.), R01 AA020703, R01 AA24726, U01 AA026939, and by Award Number BX004594 from the Biomedical Laboratory Research & Development Service of the VA Office of Research and Development (to B.S.) and services provided by P30 DK120515 and P50 AA011999.
Preview

Abstract

Alcohol-associated liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are important causes of morbidity and mortality worldwide. The intestinal microbiota is involved in the development and progression of both ALD and NAFLD. Here we describe associated changes in the intestinal microbiota, and we detail randomized clinical trials in ALD and NAFLD which evaluate treatments modulating the intestinal microbiome including fecal microbiota transplantation, probiotics, prebiotics, synbiotics, and antibiotics. Finally, we discuss precision medicine approaches targeting the intestinal microbiome to ameliorate ALD and NAFLD.



Publikationsverlauf

Artikel online veröffentlicht:
14. Januar 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA